ARVINAS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARVINAS, INC. (ARVN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.80 million shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-04
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.80M shares.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 12.50M shares, a 20.19% increase year-over-year.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 13.80M shares, a 28.97% increase year-over-year.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 10.40M shares, a 14.29% increase year-over-year.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.20M shares, a 19.61% increase from fiscal 2024.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.20M shares, a 12.09% increase from fiscal 2023.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.10M shares, a 24.66% increase from fiscal 2022.
- ARVINAS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.30M shares, a 35.19% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | 13.80M shares 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | 12.20M shares 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | 12.50M shares 10-Q · filed 2025-11-05 | 12.50M shares 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 13.80M shares 10-Q · filed 2026-08-04 | ||||
| 2024-12-31 | 10.20M shares 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | 10.40M shares 10-Q · filed 2025-11-05 | 10.40M shares 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 10.70M shares 10-Q · filed 2025-08-06 | 10.70M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 11.10M shares 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | 9.10M shares 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | 9.10M shares 10-Q · filed 2024-10-30 | 9.10M shares 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | 9.30M shares 10-Q · filed 2024-07-30 | 9.30M shares 10-Q · filed 2024-07-30 | |||
| 2023-03-31 | 9.30M shares 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | 7.30M shares 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | 7.10M shares 10-Q · filed 2023-11-07 | 7.10M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 6.80M shares 10-Q · filed 2023-08-08 | 6.80M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 6.60M shares 10-Q · filed 2023-05-05 | ||||
| 2021-12-31 | 5.40M shares 10-K · filed 2024-02-27 | 2.60M shares 10-K · filed 2022-02-28 | |||
| 2021-09-30 | 5.50M shares 10-Q · filed 2022-11-09 | 5.50M shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 5.60M shares 10-Q · filed 2022-08-04 | 5.60M shares 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 5.70M shares 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | 4.60M shares 10-K · filed 2023-02-23 | 4.69M shares 10-K · filed 2021-03-01 | |||
| 2020-09-30 | 4.98M shares 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | 5.02M shares 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | 5.06M shares 10-Q · filed 2020-04-28 | ||||
| 2019-12-31 | 1.20M shares 10-K · filed 2022-02-28 | 4.19M shares 10-K · filed 2020-03-16 | |||
| 2019-09-30 | 4.25M shares 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | 4.40M shares 10-Q · filed 2020-08-04 | ||||
| 2019-03-31 | 4.43M shares 10-Q · filed 2020-04-28 | ||||
| 2018-12-31 | 3.38M shares 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | 23.11M shares 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | 23.53M shares 10-Q · filed 2019-08-05 | ||||
| 2018-03-31 | 23.53M shares 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | 18.30M shares 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | 18.42M shares 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |